Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
Ampollini L, Barocelli E, Cavazzoni A, Petronini P, Mucchino C, Cantoni AM, Leonardi F, Ventura L, Barbieri S, Colombo P, Fusari A, Carbognani P, Rusca M, Sonvico F. Ampollini L, et al. Among authors: cavazzoni a. J Thorac Dis. 2018 Jan;10(Suppl 2):S207-S220. doi: 10.21037/jtd.2017.10.74. J Thorac Dis. 2018. PMID: 29507788 Free PMC article.
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A. Cavazzoni A, et al. Mol Cancer. 2012 Dec 12;11:91. doi: 10.1186/1476-4598-11-91. Mol Cancer. 2012. PMID: 23234355 Free PMC article.
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, La Monica S, Cretella D, Ravelli A, Ulivi P, Tebaldi M, Calistri D, Delmonte A, Ampollini L, Carbognani P, Tiseo M, Cavazzoni A, Petronini PG. Bonelli MA, et al. Among authors: cavazzoni a. Neoplasia. 2017 Aug;19(8):637-648. doi: 10.1016/j.neo.2017.05.003. Epub 2017 Jul 11. Neoplasia. 2017. PMID: 28704762 Free PMC article.
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
La Monica S, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Digiacomo G, Flammini L, Barocelli E, Minari R, Naldi N, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Among authors: cavazzoni a. J Exp Clin Cancer Res. 2017 Dec 4;36(1):174. doi: 10.1186/s13046-017-0653-7. J Exp Clin Cancer Res. 2017. PMID: 29202823 Free PMC article.
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S, Minari R, Cretella D, Flammini L, Fumarola C, Bonelli M, Cavazzoni A, Digiacomo G, Galetti M, Madeddu D, Falco A, Lagrasta CA, Squadrilli A, Barocelli E, Romanel A, Quaini F, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Among authors: cavazzoni a. J Exp Clin Cancer Res. 2019 May 28;38(1):222. doi: 10.1186/s13046-019-1240-x. J Exp Clin Cancer Res. 2019. PMID: 31138260 Free PMC article.
73 results